ALFAOMEGA-RETRÒ will be exploited to retrospectively collect clinical and imaging data and archival samples to be used for validation and correlative studies on markers discovered by cutting-edge translational projects within the AIRC5x1000 program "Insights into the evolving heterogeneity of colorectal cancer (CRC): from mechanism to therapies" (an ongoing multi-institutional research program).
Histologically-confirmed diagnosis of colorectal cancer (any stage).
Age >18 years at the time of diagnosis.
Availability of clinically-annotated radio-imaging data and/or diagnostic Formalin-Fixed Paraffin Embedded (FFPE) blocks (surgical resections and/or tumor biopsies), or at least 10 slides (preferably 20). FFPE tissue blocks are always preferred to slides.
Verification that the patient could not be reached for informed consent in accordance with applicable national regulations.
if inclusion criteria are not met
at least 500 colorectal cancer patients at any stage who cannot be reached for an informed consent
Cohort
Retrospective
Observation
Other interventionRetrospective Observation of standard clinical practice
Number of retrospectively recruited CRC cases
Number of retrospectively recruited CRC cases with complete matched clinical data, radio-imaging data and FFPE or frozen biological samples.
Number of new prognostic and predictive markers
Number of identified/validated new independent prognostic and predictive biomarkers
Biomarkers correlation with PFS
Correlation of new prognostic and predictive biomarkers with progression-free survival (PFS).
Biomarkers correlation with OS
Correlation of new prognostic and predictive biomarkers with overall survival (OS).
Click on the lead sponsor to view all of their trials.
